Moonlake Immunotherapeutics ((MLTX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MoonLake Immunotherapeutics is conducting a Phase 3 clinical study titled ‘Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response.’ The study aims to assess the efficacy and safety of sonelokimab, a novel treatment for adults with active psoriatic arthritis who have not responded adequately or have shown intolerance to anti-TNFα therapy. This research is significant as it seeks to provide an alternative treatment option for this patient group.
The study tests the drug sonelokimab, administered subcutaneously, against a placebo and an active comparator, risankizumab. Sonelokimab is designed to reduce inflammation and improve symptoms in patients with psoriatic arthritis.
This randomized, parallel-group study involves four arms, including two doses of sonelokimab, a placebo, and risankizumab as an active comparator. The trial employs triple masking to ensure unbiased results, with the primary purpose being treatment evaluation.
The study began on October 11, 2024, with primary completion expected in the following months. The latest update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update from MoonLake Immunotherapeutics could positively influence their stock performance, as successful results may lead to a new treatment option for psoriatic arthritis, potentially increasing market share. Investors should also consider the competitive landscape, as other companies are developing similar therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.